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The pathogenesis of the slow virus encephalopathies and multiple sclerosis is reviewed within
the framework of the immune response. The diseases are analyzed for the component of the
immune response that appears to be crucial to the host's failure tocontrol the disease. Thus, the
absence of an immune response in the spongiform encephalopathies appears to reflect a failure
ofantigen recognition. Progressive multifocal leukoencephalopathy (PML), subacute sclerosing
panencephalitis (SSPE), and progressive rubella panencephalitis (PRP) may result principally
from a failure ofeffector mechanisms. In PMLthe failure usually occurs within the setting ofan
immunosuppressive illness. Conversely, in SSPE and PRP the effector failure seems to result
from the nature of the host-virus interaction itself. Finally, evidence is accumulating that a
defect of immunoregulation plays a significant role in multiple sclerosis.
INTRODUCTION
Despite remarkable progress, we are ignorant of much of the pathogenesis of the
"slow virus" encephalopathies and M.S. For example, in progressive multifocal
leukoencephalopathy (PML) it is thought that a papova virus attack on oligoden-
droglia is responsible for the impairment of myelin production. It is not known,
however, what specific effector mechanism is required to prevent viral replication in
the brain. Subacute sclerosing panencephalitis (SSPE) is associated with anabortive
measles virus infection of the brain and a marked antibody response. What is not
known are the features of the host-virus interaction which render the host defense
response ineffective. In Creutzfeld-Jakob Disease (CJD) there is no evidence that the
host recognizes any antigenicity in the transmissible agent. Finally, M.S. is thought
by many to be a virus-induced, immune-mediated disease. Exacerbation and remis-
sion may result from fluctuation ofimmune regulation. However, this is not proven,
nor have the reasons for the fluctuation been established.
It therefore seems appropriate to review these diseases in the context of the host
immune response. The immune response will be considered as consisting ofantigen
recognition, effector mechanisms, and immunoregulation. In Table 1 the diseases are
listed under the component of the immune response which appears crucial to the
failure of the host to control the disease. This does not mean that the other
components are necessarily intact.
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Types of Immunological Failure in the
"Slow Virus" Encephalopathies and Multiple Sclerosis
1. Failure of Antigen Recognition
Kuru
Creutzfeld-Jakob Disease
2. Failure of Effector Mechanisms
A. Generalized Immune Impairment
Progressive Multifocal Leukoencephalopathy
B. Specific Interactions of Host and Virus
Subacute Sclerosing Panencephalitis
Progressive Rubella Panencephalitis
3. Failure of Immunoregulation
Multiple Sclerosis
FAILURE OF ANTIGEN RECOGNITION: KURU AND CJD
Experimental transmissibility ofa fatal subacute encephalopathy with characteris-
tic neuropathological changes are common features ofthe spongiform encephalopa-
thies. These are scrapie and transmissible mink encephalopathy ofanimals and Kuru
and CJD of humans [1]. Kuru, found exclusively in New Guinea, was transmitted to
subhuman primates by Gajdusek and his colleagues. It has declined markedly since
the termination of ritual cannibalism. CJD, in contrast, isfound in many parts ofthe
world. Its central clinical effect is dementia with myoclonic jerks and an electroen-
cephalographic pattern of burst suppression. The neuropathological changes consist
of the spongiform change, loss of neurons, and proliferation of glia [2].
Although extremely high infectivity titers in infected brain can be measured by
transmission to experimental animals, conventional virus has not been isolated.
Furthermore, these agents are unusually resistant to many treatments that destroy
infectivity of conventional agents such as nucleases, proteases, heat (800C), UV
irradiation, and formaldehyde. They do, however, appear to be vulnerable to
treatments which disrupt membranes [1], suggesting that they may be closely
associated with host membranes. The insensitivity to conventional inactivation
techniques coupled with accidental surgical transmission in humans has led to the
formulation of safety procedures for handling CJD patients [3].
One ofthe most remarkable features of all the spongiform encephalopathies is the
absence of any evidence of a host defense response. The brain contains no features of
inflammation such as mononuclear perivascular infiltration, glial nodules, or phago-
cytic cells. Although the CSF protein may be mildly elevated, there is no CSF
pleocytosis [4]. No evidence of serum neutralizing activity has been found, nor is
there evidence ofdeposition ofimmune complexes. Furthermore, attempts to induce
in vitro blastogenesis of leukocytes of diseased animals with infected material have
failed [5]. Finally, it has not been possible to immunize against CNS disease in
experimental scrapie infection of goats [6]. Thus, there is no evidence that antigen
recognition occurs on exposure to this class of agent. Since disease does not occur in
the setting of an immunocompromised host, it seems most likely that the failure of
recognition relates to the agent itself. Demonstration or experimental induction of
antigen recognition would be a significant contribution to the understanding ofthese
diseases.
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FAILURE OF EFFECTOR RESPONSE
Generalized Immune Impairment:PML
PML is a rare demyelinating disease of the central nervous system often occurring
in the setting
of an immunosuppressive systemic illness [7].
The neuropathology is
characterized by foci ofdemyelination, bizarre apparently transformed astroglia, and
destruction of oligodendroglia involving enlargement, intranuclear inclusions, and
lysis. Papova virus originally identified by electronmicroscopy (E.M.) [8] has been
isolated from PML diseased brains [9].
It is felt that the diverse clinical symptomatol-
ogy results from impairment of myelin production in papova virus-infected oligoden-
droglia.
All but two isolates of papova virus from
PML material have been the JC virus
(JCV) type,
the other being SV40 [10]. JCV,
a papova virus,
is antigenically
distinct from SV40 and from the human wart virus. It can be grown in primary
cultures of fetal glial cells in which evidence of both cell lysis and cellular enlargement
are found[10]. Recently it has been reported to replicate in human amnion cells [ 11].
It has been demonstrated that JCV is oncogenic in vivo [10].
The virus contains a
hemagglutinin which has led to the development of an hemagglutination-inhibition
test for antibody. Utilizing this assay, Padgett and Walker found that 69 percent of
adults sampled in Wisconsin had antibody to JCV [12].
Often occurring in the setting of an illness which depresses the host defense
capability, PML may involve a number of nonspecific humoral and cell-mediated
immunity (CMI) defects. For example, Narayan et al.
described immunological
testing in five reported patients with PML [13]. The defects ranged from an isolated
failure of lymphocytes respond in vitro to phytohemagglutinin to combined
defects of humoral and cell-mediated immunity. With regard to viral specific
responses
there has been documentation of humoral antibody to in patients with
PML [10,14]. Assays
of CMI toward JCV are just beginning to be examined.
Willoughby
et al. have recently reported on six patients with who had
detectable antibody
to JCV [14]. No leukocyte inhibition factor was induced on
exposure
to JCV antigen when leukocytes from these patients were used,
but it was
induced from controls previously exposed to the virus.
this data is confirmed it
would appear
that antigen recognition occurred but that CMI was deficient. A
critical question
will then be to determine the nature of the protective effector
mechanism.
Speciifc Interactions of Host and Virus:SSPE and PRP
SSPE,
a disease of childhood, has a median age of onset of about nine years [15]. It
follows an average
of seven years after an apparently uncomplicated case of measles.
The initial measles infection frequently occurs by two years of age [16].
The course of
SSPE is from
less than year to a few years.
is fatal in at least percent of cases
with survival occasionally reported [17].
The course has been characterized as going
through
four stages beginning with behavioral abnormalities [18].
This is followed by
the development
of myoclonic jerks and spasticity,
which evolves into marked
spasticity
and coma,
with final evolution to a reduction of myoclonus and spasticity
prior
to death. Males attacked more frequently than females,
and in the United
States the highest
attack rates are in the Southeast and upper Ohio River Valley [15].
Cases of SSPE, described as other entities,
can be found in the literature of
neuropathology
as early (reviewed in [19]).
The principal neuropathological
103features are widespread distribution of perivascular mononuclear infiltrates, fibril-
lary gliosis, demyelination, and Cowdry type A intranuclear inclusion bodies. The
description of myxovirus nucleocapsid material in brain material by Bouteille et al.
(cited in [19]) on E.M. initiated a series of observations associating abortive measles
virus infection with SSPE. Later, Connolly et al. documented unusually high anti-
measles antibody levels in serum and CSF [20]. Finally, Horta-Barbosa et al.
reported the successful isolation of extracellular measles virus by cocultivation of
passaged brain cells with a susceptible cell line [21].
A critical question concerning SSPE isolates is whether they differ consistently
from measles virus. Hall and ter Muelen have reported that the genome of SSPE
isolates contains 10 percent more information than measles virus genome [22].
Furthermore, Hall et al. have shown that the mRNA coding for the matrix (M)
polypeptide has a higher molecular weight in SSPE virus than in measles virus and
that the respective M proteins are antigenically distinct [23]. Concurrently, Wechsler
and Fields reported that the M polypeptide offive SSPE isolates migrated differently
than that of the Edmonston strain of measles virus [24]. Hall et al. did not find an
electrophoretic pattern characteristic of SSPE virus [25]. They did find a relative lack
of antibodies to the M protein in sera from SSPE patients. The role of the M
polypeptide is presumed to be in nucleocapsid and cell membrane recognition during
virus maturation. The effect ofthe altered M polypeptide in SSPE is not known. One
possibility is that it might produce a measles-infected cell which is not susceptible to
cytotoxic effector mechanisms of the host.
One of the major problems in understanding the pathogenesis of SSPE is the
repeated demonstration of antiviral effector function in patients. Specific humoral
immune function is demonstrated by high levels of circulating and locally produced
antibody [18]. The presence of cell-mediated cytotoxicity against measles-infected
targets has been demonstrated in vitro [26,27,28]. How then does the virus survive in
the face of specific effector capability? At present there are at least three mechanisms
resulting from virus host cell interaction to explain the failure of host effector
mechanisms. First, circulating and CSF factors that block immune responses,
possibly immune complexes, have been described [29]. Second, the proposal has been
made by Oldstone and his colleagues that antibody strips viral antigen from infected
cells, resulting in an antigenically modulated target no longer susceptible to cytotox-
icity. That group has recently shown that surface antibody can also alter the
production of viral protein within the cell [30]. Finally, an altered M polypeptide
might result in a measles-infected cell no longer recognized by host cytotoxic effector
mechanisms. The relative lack of antibodies to the M polypeptide in SSPE supports
this concept [25].
The remarkable clinical pattern of SSPE, initial infection and resolution followed
years later by a relentlessly progressive panencephalitis, also occurs in progressive
rubella panencephalitis (PRP). Although incompletely characterized because of the
paucity of reported cases, PRP has not been associated with a generalized defect of
humoral or cell-mediated immunity [31]. The onset at the start of the second decade
follows congenital or childhood rubella and progresses relentlessly over a few years
with dementia and ataxia as principal features. Cerebellar atrophy, white matter
destruction, perivascular infiltration, neuronal loss, gliosis, and amorphous vascular
deposits characterize the neuropathology [32]. Rubella virus has been isolated from
the brain and locally produced anti rubella antibody is found in the CSF [33]. The
CSF IgG is elevated and oligoclonal bands containing anti rubella antibody are
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found [34]. Thus, PRP is an illness in which viral antigens are recognized and a
specific immune response produced. However, like SSPE, interaction of the virus
and the host apparently allows the establishment of latency and, years later, the
emergence of a destructive CNS disease.
FAILURE OF IMMUNOREGULATION: M.S.
Multiple sclerosis was established as a clinical-pathological entity over a century
ago by J.M. Charcot. It strikes people between the ages of 10 and 50, impairs the
function of multiple
areas of white matter,
and usually has a characteristic exacerbat-
ing
and remitting
course. Although
it has long been suspected that M.S. has a viral
etiology,
no consistent proof for any single virus has emerged. However,
the disease
appears
to be mediated by immune mechanisms.
The neuropathology is essentially
one of an inflammatory demyelinating process [35]. Active areas ofdemyelination, or
plaques,
have a rim of mononuclear cells,
and the plaques can be shown to contain
IgG [36,37]. Furthermore, high association between M.S.
and certain B lymphocyte
alloantigens
has been demonstrated [38,39]. Finally,
the most consistent laboratory
abnormality, but not diagnostic, is evidence of local CNS production of IgG as
reflected in the cerebrospinal fluid.
With the use of isoelectric focusing,
the presence
of oligoclonal
bands of IgG has been found in the CSF of over 90 percent of patients
with M.S. [40].
Although
the immune specificity of the majority of the immunoglobulin in the
CSF is undefined (reviewed in [41]), antibody to measles, vaccinia,
and other viruses
has been found in the CSF in the absence of a breakdown of the blood-brain barrier
or the demonstration of ongoing
CNS infection. Thus, virus-specific antibody
localized to the central nervous system is found in the apparent absence of the
inducing agents.
One explanation of this data would be the failure of the shutoff
signal, immunosuppression, for antibody-forming cells in patients with M.S. Evi-
dence for the non-specificity of the failure of immunosuppression is found in the
work of Norrby
et al. [42]. They found antibody in the CSF to measles in 57 percent,
rubella in 19 percent, mumps in percent, herpes in 11 percent,
and sendai in 3
percent
of 150 patients
with M.S. Furthermore, antibody to two viruses was found in
16 percent
and to three viruses was found in 7 percent.
This indicates that than
one antibody-producing clone has failed to shut down and that the multiple antibody
responses
are not directed toward multiple antigenic determinants on single
complex agent.
The most likely interpretation is failure of polyclonal immunosup-
pression.
The concept
that there is a failure of immunosuppression is supported by
experimental
studies peripheral mononuclear cells in vitro for suppressor activity.
Arnason
and Antel demonstrated a marked reduction in vitro of suppressor cell
activity
that could be induced by Concanavalin during exacerbations of M.S.
with
a rebound of excess activity during recovery [43].
Our own pilot studies [44] and the
studies of Neighbor Bloom [45] support the finding of a failure of Concanavalin
A induceable immunosuppression during exacerbations of M.S.
The latter investiga-
tors found a reduced measles antigen induced suppressor activity irrespective of
disease activity. Finally, Huddlestone and Oldstone found a transient decrease of
circulating suppressor cells during disease exacerbation [46]. Clearly several crucial
questions
arise. If
one could prevent impairment of suppressor cell function,
could
exacerbations be prevented? One would also like to know what causes the transient
impairment of suppressor cell function.
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CONCLUSION
Although the diseases have been discussed as reflecting types of failure ofthe host
immune response, it is not anticipated that these defects will turn out to be isolated.
Thus, it is entirely possible that defects of more than one type will be found in any
given disease. It is hoped, however, that this analysis will generate experimental
questions about the pathogenesis of the diseases.
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